Declaration of Interest Form

Professor Graham Roberts
Submitted:

Your Information
First Name
Graham
Last Name
Roberts
Date of completion
2021-11-11

Please tell us all the BSACI Committees/Groups you are a member of, or if you are a speaker please name the event (E.G. WAO/BSACI 2022)
Trustees Council Paediatric Committee

Initial Declaration
Do you have any Conflicts of Interest that you need to declare?
yes

Personal Benefits
1. Ongoing Personal Benefit(s)
2. Personal Benefit(s) completed within the last year
3. Personal Benefit(s) completed 1-2 years ago
4. Personal Benefit(s) completed 2-3 years ago

Personal Travel Grants/Expenses for Conferences etc..
1. Ongoing Personal Travel Grants/Expenses for Conferences
2. Personal Travel Grants/Expenses for Conferences received within the last year
3. Personal Travel Grants/Expenses for Conferences received within 1-2 years
4. Personal Travel Grants/Expenses for Conferences received within 2-3 years

Personal Shares
Personal Share(s)

Non-Personal Interests
1. Ongoing Non-personal interests
Research funding from NIHR, AMR, NIH, EU.

2. Non-personal interests completed within the last year
Mylan for advisory board attendance
ALK-Abello for advisory board attendance and company symposia
Ga2len for online webinars
DBV for advisory board attendance

3. Non-personal interests completed within 1-2 years
Allergy Therapeutics for advisory board attendance
Astra Zeneca for advisory board attendance
DBV for advisory board attendance
ALK-Abello for activities as investigator in clinical trial

4. Non-personal interests completed within 2-3 years
ALK-Abello for advisory board attendance
Euforea for symposium

Other potential conflicts of interest
1. Ongoing Conflict of interest
   BSACI member
   EAACI member - chair of adolescent and young adult taskforce
   RCPCH member
   BMA member
   BTS member

2. Conflict of interest within the last year
3. Conflict of interest within 1-2 years
4. Conflict of interest within 2-3 years

Additional Interests
Additional interest
Patent for use of HDM immunotherapy as a preventative intervention